Use of etanercept in a patient with rheumatoid arthritis on hemodialysis

Modern Rheumatology

Volumn 18, Issue 3, 2008, Pages 293-295

  Sugioka, Yuko ^a   Inui, Kentaro ^b   Koike, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Higashisumiyoshi Morimoto Hospital   (Japan)

Author keywords

Etanercept; Hemodialysis; Rheumatoid arthritis

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; PREDNISOLONE; RHEUMATOID FACTOR;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; COMORBIDITY; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; JAPANESE; JOINT SWELLING; KIDNEY FAILURE; LABORATORY TEST; PATIENT REFERRAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RENAL DIALYSIS;

EID: 46549085737     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0041-4     Document Type: Article

References (14)

1. Stokes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum. 2003;33:1-18.
2. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003;73:348-65.
3. Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol. 2005;57:1407-13.
4. Nakamura M, Sakemi T, Nagasawa K. Severe pancytopenia caused by a single administration of low dose methotrexate in a patient undergoing hemodialysis. J Rheumatol. 1999;26:1424-5.
5. Akiyama Y, Fujimaki T, Sakurai Y. Pharmacokinetics of salazosulfapyridine in a hemodialysis patient (in Japanese). Ryumachi. 2003;43:569-76.
6. Hamada K. The safety of actarit (mover) in hemodialysis patients with rheumatoid arthritis (in Japanese). Prog Med. 1997;17:1652-7.
7. Kaizu K, Komine N, Uriu K, Ikeda M, Hashimoto O, Eto S. Bucillamine may be an effective anti-rheumatic drug in patients with end-stage renal disease - a case report (in Japanese). J Jpn Soc Dial Ther. 1994;27:1505-10.
8. Matthey F, Perrett D, Greenwood RN, Baker LRI. The use of d -penicillamine in patients with rheumatoid arthritis undergoing hemodialysis. Clin Nephrol. 1986;25:268-71.
9. Saisho K, Kurosawa O, Fukanoki T, Hanafusa A, Tajima N. Long-term use of mizoribine in rheumatoid arthritis patients on hemodialysis. Mod Rheumatol. 2001;11:132-5.
10. Beaman JM, Hackett LP, Luxton G, Illett KF. Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother. 2002;36:75-7.
11. Gruber SA, Hewitt JM, Sorenson AL. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol. 1994;34:859-64.
12. Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation. 1994;57:483-9.
13. Singh R, Cuchacovich R, Huang W, Espinoza LR. Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol. 2002;29:636-7.
14. Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford). 2006;45:357-9.